Clinical Trial Update: Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial of Actinium-225-labeled HuM195 (lintuzumab) for advanced myeloid malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Actinium-225-labeled HuM195 (lintuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED